Trial Profile
Phase I Dose-Escalating Study of Combining Intravenous Tirapazamine and Transarterial Embolization (TAE) in Liver Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 25 Sep 2023
Price :
$35
*
At a glance
- Drugs Tirapazamine (Primary)
- Indications Carcinoma; Liver cancer; Liver metastases; Neuroendocrine tumours; Solid tumours
- Focus First in man; Therapeutic Use
- Sponsors Teclison
- 19 Sep 2023 Primary endpoint has been amended and trial focus has been shifted to Tu, Age criteria of patient inclusion has been changed (20 to 99 year), Planned number of patients changed from 50 to 25.
- 19 Sep 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2025.
- 19 Sep 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2025.